Vancouver, BC — (February 26, 2016) — GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / FRANKFURT: GHG / OTCQB: GBHPF) is pleased to announce that Mr. Frank Giese has joined the Company’s Advisory Board to assist in the development of the newly formed Genetics Division.
Mr. Giese is an expert cannabis cultivator and breeder, Medical Marijuana (MMJ) contractor and MMJ systems analyst. For nearly 10 years, when medical cannabis legislation was passed permitting possession and cultivation in his home state of Washington, Mr. Giese combined his over 25 years of practical field experience working for government agencies as a research biologist extensively focusing on DNA, genetic identification and breeding of endangered species, with education and business expertise to begin breeding medical cannabis strains.
This widely varied combination of backgrounds along with many years of research and hard work has allowed him to become a true master cannabis cultivator and breeder. Mr. Giese has bridged the fundamentals of scientific research and cannabis breeding, as well as the use and development of modern cultivation and processing techniques in his breeding work. He has become proficient in breeding CBD rich strains, as well as being very experienced in auto flower breeding.
Mr. Giese’s current cannabis breeding efforts are focused on commercially viable, rapidly maturing varieties and his continued efforts in the development of new industrial hemp cultivars. His vision for the future is to introduce modern growing techniques to industrial hemp, as has been done with cannabis.
Mr. Giese has been involved in the installation and/or modification of more than 100 medical cultivation facilities as an MMJ contractor; from small to large scale outdoor grow operations, state-of-the-art Sealed Environment Grow (SEG) facilities (indoor), as well as associated processing and retail facilities. He has also been contracted as a consultant or MMJ systems analyst to access cultivation operations and recommend modifications to increase productivity, reduce costs and/or other specified objectives.
Mr. Giese will advise management on matters relating to hemp and cannabis genetics and other industry opportunities within the states of Washington and Oregon.
“We are extremely pleased to have someone of Mr. Giese’s level of knowledge and expertise on our team to help develop this new genetics division,” stated Charles Larsen, President of Global Hemp Group. “This gives us the opportunity to advance hemp genetics used in our projects and for the industry as a whole.”
About Global Hemp Group Inc.
Global Hemp Group (“GHG”) is a publicly traded company founded in 2012, headquartered in British Columbia, Canada with base operations in Southern California, USA and having a strategic partnership in South Africa. The Company is focused on acquiring and/or joint venturing with companies across all sectors of the hemp and cannabis industries in an effort to build a “soil-to-shelf” portfolio of complementary companies that will enable GHG to capture cash flow, revenues and value from its acquisitions and establish a far greater collective valuation than GHG or the individual companies would have on their own.
On behalf of the Board of Directors
President & CEO
To view Global Hemp Group, Inc. on the Canadian Securities Exchange under symbol GHG click HERE.
Forward Looking Statements – Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Global Hemp Group Holdings Inc., including, but not limited to the impact of general economic conditions, industry conditions, volatility of commodity prices, currency fluctuations, dependence upon regulatory approvals, the availability of future financing and exploration risk. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.
The CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this